1. Home
  2. OZ vs IKT Comparison

OZ vs IKT Comparison

Compare OZ & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Belpointe PREP LLC Units

OZ

Belpointe PREP LLC Units

HOLD

Current Price

$56.00

Market Cap

245.7M

Sector

N/A

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.80

Market Cap

240.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OZ
IKT
Founded
2020
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
245.7M
240.1M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
OZ
IKT
Price
$56.00
$1.80
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
18.6K
1.3M
Earning Date
05-19-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.76
EPS
N/A
N/A
Revenue
$9,187,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$33.33
P/E Ratio
N/A
N/A
Revenue Growth
243.44
N/A
52 Week Low
$48.50
$1.33
52 Week High
$69.00
$2.37

Technical Indicators

Market Signals
Indicator
OZ
IKT
Relative Strength Index (RSI) 62.10 47.70
Support Level $49.78 $1.43
Resistance Level $57.35 $1.88
Average True Range (ATR) 2.11 0.12
MACD 0.21 -0.01
Stochastic Oscillator 78.71 35.29

Price Performance

Historical Comparison
OZ
IKT

About OZ Belpointe PREP LLC Units

Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Share on Social Networks: